MX2019010895A - Formulacion liquida de anticuerpo anti-tnf alfa. - Google Patents

Formulacion liquida de anticuerpo anti-tnf alfa.

Info

Publication number
MX2019010895A
MX2019010895A MX2019010895A MX2019010895A MX2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A
Authority
MX
Mexico
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
MX2019010895A
Other languages
English (en)
Inventor
Yun Sora
Kyung Ko Youn
Eon So Jin
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010895(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2019010895A publication Critical patent/MX2019010895A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación líquida de un anticuerpo contra TNF-a, específicamente a una formulación líquida de adalimumab.
MX2019010895A 2017-03-16 2018-03-16 Formulacion liquida de anticuerpo anti-tnf alfa. MX2019010895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
MX2019010895A true MX2019010895A (es) 2019-11-05

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010895A MX2019010895A (es) 2017-03-16 2018-03-16 Formulacion liquida de anticuerpo anti-tnf alfa.

Country Status (15)

Country Link
JP (2) JP7109849B2 (es)
KR (2) KR20180106974A (es)
CN (1) CN110621303A (es)
AU (1) AU2018236651B2 (es)
BR (1) BR112019019162A2 (es)
CO (1) CO2019010860A2 (es)
MA (1) MA46988A1 (es)
MX (1) MX2019010895A (es)
MY (1) MY197202A (es)
NZ (1) NZ757965A (es)
PH (1) PH12019502075A1 (es)
RU (1) RU2756619C2 (es)
UA (1) UA123847C2 (es)
WO (1) WO2018169348A1 (es)
ZA (1) ZA201906696B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
CN103458926B (zh) * 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG10201609982PA (en) * 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
EP2948473A1 (en) * 2013-01-24 2015-12-02 GlaxoSmithKline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
AR095496A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
EP3050557A1 (en) * 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP2020510079A (ja) 2020-04-02
MY197202A (en) 2023-05-31
JP2022097600A (ja) 2022-06-30
RU2019130728A3 (es) 2021-04-16
KR20200096472A (ko) 2020-08-12
JP7109849B2 (ja) 2022-08-01
WO2018169348A1 (ko) 2018-09-20
CO2019010860A2 (es) 2020-01-17
AU2018236651A1 (en) 2019-10-31
UA123847C2 (uk) 2021-06-09
KR20180106974A (ko) 2018-10-01
PH12019502075A1 (en) 2020-09-14
MA46988A1 (fr) 2020-06-30
RU2756619C2 (ru) 2021-10-04
AU2018236651B2 (en) 2020-12-10
NZ757965A (en) 2022-07-01
KR102342292B1 (ko) 2021-12-24
ZA201906696B (en) 2020-08-26
BR112019019162A2 (pt) 2020-04-14
RU2019130728A (ru) 2021-04-16
CN110621303A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MY198059A (en) Anti-ox40 antibodies and their uses
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY191581A (en) Anti-pd-1 antibodies
MY193661A (en) Anti-tim3 antibodies and methods of use
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2023006416A (es) Anticuerpos, usos y metodos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2020006758A (es) Cemento de alumina.
AU2018279184A1 (en) Anti-TrkB antibodies
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2017016258A (es) Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.